BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36276992)

  • 1. PDP1 Promotes Cell Malignant Behavior and Is Associated with Worse Clinical Features in Ovarian Cancer Patients: Evidence from Bioinformatics and In Vitro Level.
    Song Y; Zhang J; Zhang L; Zhang S; Shen C
    Comput Math Methods Med; 2022; 2022():7397250. PubMed ID: 36276992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
    Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
    Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis.
    Zeng Q; Yi C; Lu J; Wang X; Chen K; Hong L
    Cancer Med; 2023 Apr; 12(7):9024-9040. PubMed ID: 36708070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
    Li Y; Li L
    J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive bioinformatics analysis confirms RBMS3 as the central candidate biological target for ovarian cancer.
    Wang M; Fu X; Wang W; Zhang Y; Jiang Z; Gu Y; Chu M; Shao Y; Li S
    Med Eng Phys; 2022 Dec; 110():103883. PubMed ID: 36075788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and
    Yu Y; Wang Y; Zou Y; Yu Y
    Dis Markers; 2022; 2022():5286820. PubMed ID: 35707714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
    Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
    Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCNB1, Negatively Regulated by miR-559, Promotes the Proliferation, Migration, and Invasion of Ovarian Carcinoma Cells.
    Yang X; Zhou S; Yang C; Cao C; He M; Zi S
    Mol Biotechnol; 2022 Sep; 64(9):958-969. PubMed ID: 35262876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
    Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
    J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Analysis of Gene Biomarkers for Ovarian Cancer.
    Wang X; Xie C; Lu C
    Genet Test Mol Biomarkers; 2024 Feb; 28(2):70-81. PubMed ID: 38416665
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and Validation of the Diagnostic Characteristic Genes of Ovarian Cancer by Bioinformatics and Machine Learning.
    Liu J; Liu L; Antwi PA; Luo Y; Liang F
    Front Genet; 2022; 13():858466. PubMed ID: 35719392
    [No Abstract]   [Full Text] [Related]  

  • 13. Intracellular matrix Gla protein promotes tumor progression by activating JAK2/STAT5 signaling in gastric cancer.
    Wang M; Chen L; Chen Y; Wei R; Guo Q; Zhu S; Guo S; Zhu S; Zhang S; Min L
    Mol Oncol; 2020 May; 14(5):1045-1058. PubMed ID: 32086862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J; Liu L
    J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.
    Zheng MJ; Li X; Hu YX; Dong H; Gou R; Nie X; Liu Q; Ying-Ying H; Liu JJ; Lin B
    J Cell Physiol; 2019 Jul; 234(7):11023-11036. PubMed ID: 30633343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of IRF6 related to ovarian cancer and biological function and prognostic value.
    Hong S; Fu N; Sang S; Ma X; Sun F; Zhang X
    J Ovarian Res; 2024 Mar; 17(1):64. PubMed ID: 38493179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
    Zuo L; Li X; Tan Y; Zhu H; Xiao M
    J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
    Yang KS; Xu CQ; Lv J
    Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer.
    Li F; Zhang Y; Shi Y; Liu S
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):71-79. PubMed ID: 34587437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAD51AP1 promotes progression of ovarian cancer via TGF-β/Smad signalling pathway.
    Zhao H; Gao Y; Chen Q; Li J; Ren M; Zhao X; Yue W
    J Cell Mol Med; 2021 Feb; 25(4):1927-1938. PubMed ID: 33314567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.